N-丁基吡咯烷-3-羧酸 | 122079-54-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: N-丁基吡咯烷-3-羧酸
• 中文别名: 吡咯烷-3-甲酸丁酯；吡咯烷-3-羧酸正丁酯
• 英文名称: Butyl pyrrolidine-3-carboxylate
• CAS: 122079-54-3
• 化学式: C₉H₁₇NO₂
• 分子量: 171.239
• InChiKey: GPAHFRRSJVMHAT-UHFFFAOYSA-N

物化性质

• 沸点：
  231.6±33.0 °C(Predicted)
• 密度：
  0.996±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  聚合甲醛 、 丙烯酸丁酯 、 聚甘氨酸 以 甲苯 为溶剂， 反应 2.0h， 以98%的产率得到N-丁基吡咯烷-3-羧酸
  参考文献：
  名称：

  Joucla, Marc; Mortier, Jacques, Bulletin de la Societe Chimique de France, 1988, # 3, p. 579 - 583

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS<br/>[FR] AMIDES DE N-PHÉNYL-PYRROLIDINYLMÉTHYLPYRROLIDINE SUBSTITUÉS ET LEUR UTILISATION THÉRAPEUTIQUE COMME MODULATEURS DU RÉCEPTEUR H3 DE L'HISTAMINE
  申请人：SANOFI AVENTIS

  公开号：WO2009052063A1

  公开（公告）日：2009-04-23

  The present invention discloses and claims a series of substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides of formula (I) as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this invention also discloses methods of preparation of substituted pyrrolidinylmethylpyrrolidine amides and intermediates therefor.

  本发明公开并要求一系列如下所述的化合物的N-苯基-吡咯啉甲基吡咯啉酰胺，其化学式为(I)。更具体地，本发明的这些化合物是H3受体的调节剂，因此在治疗和/或预防包括与中枢神经系统相关的多种疾病在内的受H3受体调节的疾病中可用作药物。此外，本发明还公开了替代吡咯啉甲基吡咯啉酰胺及其中间体的制备方法。
• SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF
  申请人：CZECHTIZKY Werngard

  公开号：US20100173898A1

  公开（公告）日：2010-07-08

  The present invention discloses and claims a series of substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides of formula (I). Wherein R, R 1 , R 2 , R 3 and R 4 are as described herein. More specifically, the compounds of this invention are modulators of H3 receptors and are, therefore, useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system. Additionally, this invention also discloses methods of preparation of substituted pyrrolidinylmethylpyrrolidine amides and intermediates therefor.

  本发明揭示并声明了一系列化合物，其为N-苯基-吡咯烷甲基吡咯烷酰胺的取代物，其化学式为(I)，其中R、R1、R2、R3和R4如本文所述。更具体地说，本发明的化合物是H3受体的调节剂，因此在治疗和/或预防多种由H3受体调节的疾病中，特别是中枢神经系统相关疾病中，具有药物学上的用途。此外，本发明还揭示了制备取代的吡咯烷甲基吡咯烷酰胺及其中间体的方法。
• SUBSTITUTED N-PHENYL-PYRROLIDINYLMETHYLPYRROLIDINE AMIDES AND THERAPEUTIC USE THEREOF AS HISTAMINE H3 RECEPTOR MODULATORS
  申请人：Sanofi-Aventis

  公开号：EP2205558A1

  公开（公告）日：2010-07-14
• NOVEL HETEROCYCLIC COMPOUNDS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20220396565A1

  公开（公告）日：2022-12-15

  Provided are novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R 1 to R 4 , m, n, and p are as described herein. Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
• US8227504B2
  申请人：——

  公开号：US8227504B2

  公开（公告）日：2012-07-24